News
LXEO
5.50
-4.51%
-0.26
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
TipRanks · 2d ago
Stifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 2d ago
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital
TipRanks · 2d ago
Trump Trade: U.S. plans AI security order without required model tests
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO)
TipRanks · 3d ago
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 3d ago
Lexeo Therapeutics Price Target Maintained With a $17.00/Share by Chardan Capital
Dow Jones · 3d ago
Trump approves plan to fire FDA head Marty Makary, CBS reports
TipRanks · 3d ago
Lexeo Therapeutics reports Q1 EPS (25c), consensus (30c)
TipRanks · 3d ago
Lexeo Therapeutics GAAP EPS of -$0.25
Seeking Alpha · 3d ago
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies
TipRanks · 3d ago
*Lexeo Therapeutics 1Q Loss $20.2M >LXEO
Dow Jones · 3d ago
*Lexeo Therapeutics 1Q Loss/Shr 25c >LXEO
Dow Jones · 3d ago
Lexeo Q1 FY26 net loss narrows to $20.2 million, or $0.25 a share
PUBT · 3d ago
LEXEO THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Reuters · 3d ago
Press Release: Lexeo Therapeutics Reports First -2-
Dow Jones · 3d ago
Press Release: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Dow Jones · 3d ago
Weekly Report: what happened at LXEO last week (0504-0508)?
Weekly Report · 3d ago
Lexeo Therapeutics Reports Monday With Insiders Already Reducing Stakes
Barchart · 4d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 6d ago
More
Webull provides a variety of real-time LXEO stock news. You can receive the latest news about Lexeo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).